Name (Synonyms) | Correlation | |
---|---|---|
drug566 | Normal Saline Infusion + Maximal intensive care Wiki | 1.00 |
drug387 | Hydroxychloroquine Sulfate and Azithromycin Wiki | 1.00 |
drug61 | Ascorbic Acid and Folic Acid Wiki | 1.00 |
drug388 | Hydroxychloroquine Sulfate and Folic Acid Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.32 |
D055371 | Acute Lung Injury NIH | 0.16 |
D013577 | Syndrome NIH | 0.15 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.15 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.13 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Novel Corona Virus (COVID-19) is known to cause Acute Lung Injury/Acute Respiratory Distress Syndrome, that results in death of approximately 80% of those who develop ARDS, despite intensive care and mechanical ventilation. Patients with COVID-19 induced Acute Respiratory Distress Syndrome who are admitted for intensive care including endotracheal intubation and mechanical ventilation will be treated with Aviptadil, a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP) plus maximal intensive care vs. placebo + maximal intensive care. Patients will be randomized to intravenous Aviptadil will receive escalating doses from 50 -150 pmol/kg/hr over 12 hours.
Description: Mortality
Measure: Mortality Time: 5 Days with followup through 30 daysDescription: Index of Respiratory Distress
Measure: PaO2:FiO2 ratio Time: 5 Days with followup through the end of telemetry monitoringDescription: TNF alpha levels as measured in hospital laboratory
Measure: TNF alpha Time: 5 DaysDescription: Multi-system organ failure free days
Measure: Multi-system organ failure free days Time: 5 days with followup through 30 days